What made GlaxoSmithKline’s Hal Barron spend $2.2B to get back into neuro? Alector flashes the data
What made GSK’s Hal Barron spend $700 million cash to get in on a pair of antibodies for neurodegeneration?
Alector flashed part of the answer Thursday, detailing early data from their lead drug in a genetic and rapidly progressing form of dementia. Although it comes only from a handful of patients in a single-arm trial, it provides — after nearly a decade — one of the first hints at proof-of-concept for the approach that not only won Alector a lucrative pharma partnership but also a unicorn valuation at a time when nearly everything in neurodegeneration had failed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
